CD38 and melanoma: To begin to delineate the phenotypic and functional traits associated with CD38-expressing CD8+ T cells and their involvement in anti-PD1 resistance, we employed the highly aggressive B16-F10 melanoma tumor model, which has shown resistance to immunotherapy.